CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 13 clinical trials at NIH that match your search criteria

Cancer by type/disease: Multiple Myeloma

Trial and Protocol Number Multiple Myeloma	Principal Investigator	Referral Contact
Phase II
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study NCI-12-C-0192 , NCT01675141	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma, Followed by SC Bortezomib Maintenance NCI-12-C-0169, NCT01647165	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study NCI-11-C-0221, NCT01402284	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov
Phase I/II
Phase I/II Study of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma NCI-12-C-0179, NCT01658904	Claude Sportès 301-435-5280	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I
Multi-center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Stem Cell Transplantation in High Risk Multiple Myeloma NCI-11-C-0016, NCT01239368	Claude Sportès 301-435-5280	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Smoldering Multiple Myeloma (SMM)	Principal Investigator	Referral Contact
Phase II
MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study NCI-12-C-0180, NCT01660997	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov
No Phase
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Study NCI-12-C-0107, NCT01572480	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281, NCT00092235	Steven Z. Pavletic 301-402-4899	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome NCI-04-C-0055, NCT00074490	Daniel H. Fowler 301-435-8641	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I/II
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation NCI-09-C-0224, NCT00984165	Nancy M. Hardy 301-451-1406	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders NCI-07-C-0195, NCT00520130	Steven Z. Pavletic 301-402-4899	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies NCI-11-C-0125, NCT01326728	Nancy M. Hardy 301-451-1406	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Monoclonal Gammopathy of Undetermined Significance (MGUS)	Principal Investigator	Referral Contact
No Phase
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) NCI-10-C-0096, NCT01109407	C. Ola Landgren 301-496-0670	Marcia L. Mulquin 301-435-5613 mmulquin@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.